Last updated: September 1, 2026
The carisoprodol, aspirin and codeine phosphate combination is an established analgesic and skeletal-muscle-relaxant product with limited remaining brand protection but substantial regulatory and commercial constraints. The principal opportunity is not a novel active-ingredient patent strategy. It is a differentiated, manufacturable, regulatorily defensible formulation that manages aspirin stability, codeine uniformity, carisoprodol compatibility, abuse-deterrence expectations and controlled-substance distribution.
The historical product, commonly identified as Soma Compound with Codeine, contained carisoprodol 200 mg, aspirin 325 mg and codeine phosphate 16 mg per tablet. The product was indicated for short-term treatment of painful musculoskeletal conditions. The active ingredients are long-established, and any commercial launch would likely compete through supply reliability, dosage-form differentiation, packaging, tolerability and channel execution rather than basic molecule exclusivity.[1]
What is the composition of carisoprodol, aspirin and codeine phosphate?
The historical combination tablet used the following active ingredients:
| Component |
Typical strength per tablet |
Functional role |
| Carisoprodol |
200 mg |
Centrally acting skeletal muscle relaxant |
| Aspirin |
325 mg |
Nonsteroidal analgesic and antiplatelet agent |
| Codeine phosphate |
16 mg |
Opioid analgesic |
| Dosage form |
Tablet |
Immediate-release oral delivery |
The combination carries three different technical and regulatory burdens. Aspirin is moisture-sensitive and can hydrolyze to salicylic acid and acetic acid. Codeine requires low-dose content uniformity control and controlled-substance governance. Carisoprodol contributes dose weight and may create compression, dissolution and powder-flow challenges.
The product is intended for short-term use. The FDA label warns about sedation, impairment, dependence and withdrawal risks associated with carisoprodol and codeine. Aspirin adds gastrointestinal bleeding, ulceration, hypersensitivity and renal-risk considerations.[1]
What excipient strategy is appropriate for this combination tablet?
A conventional immediate-release tablet is the lowest-risk development platform. The formulation should prioritize chemical stability, low moisture exposure, content uniformity and rapid release of all three active ingredients.
Recommended excipient functions
| Formulation function |
Candidate excipient classes |
Strategic rationale |
| Diluent |
Microcrystalline cellulose, anhydrous dibasic calcium phosphate, mannitol |
Supports tablet weight, flow and compression |
| Binder |
Povidone, copovidone, low-substituted hydroxypropyl cellulose |
Improves granule and tablet strength |
| Disintegrant |
Crospovidone, croscarmellose sodium, sodium starch glycolate |
Supports immediate release |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Controls ejection force; excess may slow dissolution |
| Glidant |
Colloidal silicon dioxide |
Improves flow and low-dose uniformity |
| Film coat |
Hypromellose, polyethylene glycol, titanium dioxide or approved colorants |
Provides identification and limited moisture protection |
| Moisture-control packaging |
Desiccant bottle, high-barrier blister, induction seal |
Reduces aspirin degradation risk |
Anhydrous excipients are generally preferable to hydrate-containing materials where they provide equivalent performance. The main formulation objective is to reduce water activity without producing excessive tablet hardness or delayed disintegration.
A direct-compression approach may reduce manufacturing complexity, but wet granulation can improve blend uniformity and tablet robustness. The correct choice depends on the particle-size distribution, bulk density and segregation behavior of the active ingredients. Codeine phosphate is present at a materially lower level than aspirin and carisoprodol, so blend segregation is a central development risk.
How should aspirin stability influence the formulation?
Aspirin is the principal chemical-stability driver. Moisture can accelerate hydrolysis, producing salicylic acid and affecting assay, impurity levels, odor and dissolution.
A commercial formulation should use:
- Low-moisture raw materials and controlled-humidity processing.
- High-barrier packaging, particularly for multidose bottles.
- Desiccant protection where stability data support it.
- Tight control of granulation endpoint and residual moisture.
- Stability-indicating HPLC methods capable of separating aspirin, salicylic acid, carisoprodol and codeine-related substances.
Film coating can reduce environmental moisture uptake but should not be treated as a substitute for suitable primary packaging. Aluminum-aluminum blister packaging may offer a stronger stability position than standard high-density polyethylene bottles, although it increases packaging cost and may reduce convenience for institutional or chronic-dispensing channels.
Aspirin-containing products also require attention to trace metals, alkaline excipients and elevated processing temperatures. The excipient selection should avoid conditions that materially increase aspirin degradation.
What formulation patents could protect a new product?
The active ingredients and basic combination are old. A new manufacturer is unlikely to obtain meaningful patent protection for simply combining carisoprodol, aspirin and codeine phosphate in a conventional tablet.
Potentially protectable subject matter could include:
- A defined low-moisture formulation with demonstrated impurity control.
- A specific excipient ratio that improves content uniformity.
- A multiparticulate or bilayer dosage form.
- A tamper-resistant or abuse-deterrent delivery system.
- A gastroprotective or delayed-release aspirin component.
- A manufacturing process that reduces aspirin degradation.
- A packaging and formulation combination that produces a measurable shelf-life improvement.
- A taste-masked liquid or orally disintegrating formulation, subject to opioid and aspirin feasibility constraints.
Patentability would depend on novelty, non-obviousness and credible technical effects. A patent claiming routine excipient substitution is vulnerable to obviousness challenges. Stronger claims would require comparative data showing an unexpected stability, dissolution, abuse-deterrence or manufacturing benefit.
What is the FDA regulatory status of carisoprodol, aspirin and codeine phosphate?
The historical branded product is no longer a major current-market product, and its commercial status must be distinguished from the continuing regulatory status of the individual active ingredients and comparable products. FDA’s Orange Book identifies approved drug products and patent or exclusivity information, but a discontinued product is not automatically equivalent to a product withdrawn for safety or effectiveness reasons.[2]
A new product would generally require an abbreviated new drug application if the reference product and regulatory pathway support generic development. The applicant would need to establish pharmaceutical equivalence, bioequivalence, manufacturing quality and labeling conformity. If no suitable reference product or pathway is available, a 505(b)(2) application may be relevant, subject to FDA determination.[3]
The product also involves controlled-substance obligations. Carisoprodol is listed as a Schedule IV controlled substance under federal law. Codeine combination products may fall under Schedule III when they meet applicable codeine-concentration thresholds. Manufacturing, procurement, inventory, security, recordkeeping and distribution would therefore require controlled-substance compliance.[4]
When does this product lose exclusivity?
The combination has no meaningful modern exclusivity period based on the age of its active ingredients. Any original patents or regulatory exclusivities associated with the historical product have expired or are no longer commercially significant.
| Exclusivity category |
Commercial assessment |
| New chemical entity exclusivity |
Not applicable |
| Modern orphan exclusivity |
Not applicable |
| Basic active-ingredient patents |
Expired |
| Historical formulation patents |
Expected to be expired or commercially immaterial |
| Orange Book patent protection |
No current broad blocking estate is apparent for the old combination |
| Generic entry |
Legally feasible, subject to FDA reference-product and ANDA requirements |
A precise patent-expiration analysis requires product-specific Orange Book records and historical patent files. The commercial conclusion remains clear: the main barriers are regulatory execution, controlled-substance operations, quality systems and market economics rather than surviving compound patents.
What Paragraph IV challenges and patent litigation affect the product?
There is no prominent current Paragraph IV litigation landscape comparable to high-value branded drugs. A generic applicant would normally assess any Orange Book-listed patents associated with the reference product and could file a Paragraph IV certification if relevant patents remained listed.
For this old combination, the most likely outcome is a certification strategy centered on Paragraph III, Paragraph IV or a statement that no relevant patent is listed, depending on the reference product record and FDA requirements. Any litigation risk would likely involve:
- Whether a listed formulation patent remains enforceable.
- Whether the proposed product falls within a listed claim.
- Whether the reference product has an active, eligible Orange Book listing.
- Whether FDA accepts the selected reference product and dosage-form comparison.
Patent litigation is therefore a secondary risk. Regulatory product selection is the more important early decision.
What commercial opportunities exist for excipient-led differentiation?
The strongest opportunities are formulation and supply-chain improvements that solve identifiable product problems.
Moisture-stable immediate-release tablets
A high-barrier blister or desiccant-protected bottle paired with a low-moisture formulation could support a differentiated stability profile. The commercial value is highest in hot and humid markets, institutional supply and mail-order distribution.
Unit-dose packaging
Unit-dose blister packaging can improve controlled-substance accountability, reduce diversion opportunities and support pharmacy workflow. It may also reduce repeated exposure to ambient moisture compared with multidose bottles.
Abuse-deterrence positioning
An abuse-deterrent formulation could create differentiation, but the technical and regulatory threshold is high. Physical or chemical barriers would need to be meaningful for the relevant routes of abuse and supported by FDA-appropriate studies. A simple harder tablet or film coat would not establish abuse deterrence.
Layered or multiparticulate delivery
A bilayer tablet could separate aspirin from carisoprodol and codeine during processing or enable different release profiles. This approach increases manufacturing complexity and may create bioequivalence challenges. It is more suitable for a 505(b)(2) strategy than a straightforward generic program unless the reference product supports the comparison.
Lower-burden packaging and institutional supply
A reliable generic supplier could target hospitals, correctional systems, workers’ compensation networks and regional pharmacy chains. The product’s controlled-substance status makes supply continuity and traceability commercially important.
How does this product compare with competing analgesic and muscle-relaxant products?
| Product category |
Main advantage |
Main commercial weakness |
| Carisoprodol, aspirin and codeine |
Combines muscle relaxation with nonopioid and opioid analgesia |
Sedation, dependence, bleeding and controlled-substance burdens |
| Carisoprodol alone |
Simpler formulation and lower tablet complexity |
Does not provide aspirin or opioid analgesia |
| Cyclobenzaprine combinations |
Broad muscle-spasm prescribing familiarity |
Sedation and anticholinergic effects |
| NSAID plus opioid products |
Established analgesic positioning |
Opioid controls and gastrointestinal or renal risks |
| Acetaminophen-codeine products |
No aspirin-associated platelet inhibition |
Acetaminophen liver-toxicity ceiling |
| Nonopioid multimodal products |
Lower controlled-substance exposure |
May provide less immediate analgesic intensity for some patients |
The combination’s clinical differentiation is its bundled pharmacology, not superior convenience alone. That same bundle creates a narrow commercial window because many current prescribing and safety trends favor lower opioid exposure and simpler regimens.
What generic launch risks exist?
A generic launch would face six primary risks:
- Reference-product risk. The sponsor must identify an acceptable reference product and demonstrate the correct regulatory pathway.
- Bioequivalence risk. Three active ingredients create multiple analytes, dissolution profiles and pharmacokinetic endpoints.
- Stability risk. Aspirin degradation can reduce shelf life and increase batch failures.
- Controlled-substance risk. Procurement, quotas, security and distribution controls increase operating costs.
- Market-size risk. Demand may be limited by opioid stewardship, declining use of carisoprodol and prescriber preference for alternatives.
- Liability risk. Label warnings involving sedation, dependence, respiratory depression, gastrointestinal bleeding and withdrawal affect commercial uptake.
A low-cost product is unlikely to support high development spending unless a sponsor has an efficient generic platform, established controlled-substance infrastructure or a differentiated packaging strategy.
How strong is the patent estate and what geographic coverage matters?
The patent estate is weak for a conventional version of the old combination. Geographic opportunity is more likely to arise from regulatory and distribution differences than from patent exclusivity.
The United States offers a defined FDA pathway but has high controlled-substance and product-liability burdens. Canada, Europe and other markets require separate assessments of codeine scheduling, aspirin labeling, carisoprodol availability and national reimbursement. Carisoprodol is not uniformly marketed or treated the same way across jurisdictions. A multinational launch would therefore require country-specific regulatory and pharmacovigilance analysis.
Manufacturing IP may have greater practical value than composition patents. A sponsor with validated low-moisture processing, robust codeine blending and high-barrier packaging could protect know-how through trade secrets, process controls and contractual restrictions even where patent protection is limited.
Key Takeaways
- The historical product contained carisoprodol 200 mg, aspirin 325 mg and codeine phosphate 16 mg per tablet.
- The core active ingredients and basic combination are old, leaving little prospect for broad composition-of-matter protection.
- Aspirin hydrolysis and low-dose codeine uniformity are the primary formulation-development challenges.
- An immediate-release tablet with low-moisture excipients and high-barrier packaging is the lowest-risk commercial platform.
- Unit-dose packaging, stability performance, supply reliability and institutional distribution are stronger opportunities than a routine excipient substitution.
- A new product would face FDA reference-product, bioequivalence and controlled-substance requirements.
- Current commercial risk is driven by opioid stewardship, carisoprodol safety concerns, limited market size and manufacturing compliance.
- A differentiated formulation patent would require measurable technical advantages, not merely a new list of conventional excipients.
FAQs
Is carisoprodol, aspirin and codeine phosphate still commercially available?
The historical branded combination is not a major current-market product. Availability depends on the specific manufacturer, product listing and jurisdiction.
Can a manufacturer launch a generic version without a new formulation patent?
Yes. A generic product does not require a new formulation patent if it satisfies the applicable FDA approval pathway, bioequivalence standards and manufacturing requirements.
Which excipient is most important for aspirin stability?
No single excipient controls stability. Low-moisture raw materials, compatible binders and disintegrants, controlled processing humidity and protective packaging work together.
Would a bilayer tablet create meaningful patent value?
It could, but only if the bilayer architecture produces a non-obvious technical benefit, such as improved stability, dissolution control or manufacturing performance supported by comparative data.
Is codeine phosphate the main commercial barrier?
Codeine is a major barrier because of controlled-substance controls, abuse potential, labeling requirements and changing prescribing patterns. Aspirin stability and carisoprodol safety also materially affect the opportunity.
References
-
U.S. Food and Drug Administration. (n.d.). Soma Compound with Codeine prescribing information. FDA-approved labeling.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/development-resources/applications-covered-section-505b2
-
U.S. Drug Enforcement Administration. (n.d.). Controlled substance schedules. https://www.dea.gov/drug-information/drug-scheduling
